Can engineered immune cells outsmart Treatment-Resistant myeloma?

NCT ID NCT05376345

Terminated ⭐️ CURE ⭐️ Sponsor: Shanghai Changzheng Hospital Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental therapy called LCAR-BCDR, which uses a patient's own immune cells that have been engineered to recognize and attack a protein called BCMA found on myeloma cells. The study aims to see if this treatment is safe and tolerable, and whether it can shrink tumors in people with multiple myeloma that has returned or stopped responding to standard treatments. Participants will receive a conditioning regimen before the cell infusion, and researchers will monitor side effects and how long the cells persist in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LCAR-BCDR cells, a type of CAR-T cell therapy targeting BCMA
What this could lead to: If successful, this could lead to a new treatment option that may achieve long-lasting remission for patients with multiple myeloma who have not responded to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. CAR-T therapy can cause severe side effects, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Beijing Boren Hospital

Beijing, Beijing Municipality, China
Institute of Hematology & Blood Diseases Hospital

Tianjin, China
Shanghai Changzheng Hospital

Shanghai, China
Shanghai Fourth People's Hospital Affiliated to Tongji University

Shanghai, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, China
Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.